司库奇尤单抗对甲银屑病临床活动度与疾病负担的影响:随机安慰剂对照TRANSFIGURE试验32周结果
TRANSFIGURE是一项双盲、随机、安慰剂对照研究,纳入中重度斑块状和甲银屑病患者。第16周时司库奇尤单抗300mg和150mg的NAPSI改善均优于安慰剂,NAPPA生活质量总分中位下降也优于安慰剂,疗效持续至第32周。
要点
- 第16周NAPSI改善:司库奇尤单抗300mg为-45.3%,150mg为-37.9%,安慰剂为-10.8%(P<0.001)。
- 第16周NAPPA生活质量总分中位下降:300mg为60.9%,150mg为49.9%,安慰剂为15.8%(P<0.001)。
- 第32周NAPSI百分比变化:300mg为-63.2%,150mg为-52.6%。
核心结论
- 司库奇尤单抗在甲银屑病患者中显示出显著且具有临床意义的疗效和生活质量改善,持续至第32周。
研究设计与样本
- TRANSFIGURE为双盲、随机、安慰剂对照研究,纳入中重度斑块状和甲银屑病患者。
主要发现
- 第16周NAPSI改善:司库奇尤单抗300mg为-45.3%,150mg为-37.9%,安慰剂为-10.8%(P<0.001)。
- 第16周NAPPA生活质量总分中位下降:司库奇尤单抗300mg为60.9%,150mg为49.9%,安慰剂为15.8%(P<0.001)。
- 第32周NAPSI百分比变化:司库奇尤单抗300mg为-63.2%,150mg为-52.6%。
- 第16周PASI≥90改善率:司库奇尤单抗300mg为72.5%,150mg为54.0%,安慰剂为1.7%(P<0.001),并维持至第32周。
- 最常见不良事件为鼻咽炎、头痛和上呼吸道感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nail psoriasis is associated with functional impairment, pain and reduced quality of life. OBJECTIVES: To demonstrate the superiority of secukinumab over placebo in clearing nail psoriasis as assessed by the Nail Psoriasis Severity Index (NAPSI) at week 16 and over time up to week 132. Presented here is the week 32 interim analysis. Impact on quality of life was assessed by Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) patient questionnaires. METHODS: TRANSFIGURE is a double-blind, randomized, placebo-controlled study in patients with moderate-to-severe plaque and nail psoriasis. RESULTS: The primary objective of this study was met: both doses of secukinumab were superior to placebo at week 16 (NAPSI improvements of -45·3%, -37·9% and -10·8% for secukinumab 300 mg and 150 mg and placebo, respectively, P < 0·001). Significant improvements were seen in patients' quality of life: the NAPPA-Quality of Life total score median decreases at week 16 were 60·9%, 49·9% and 15·8% for secukinumab 300 mg and 150 mg and placebo, respectively (P < 0·001). Improvement in nail psoriasis continued to week 32: NAPSI percentage change reached -63·2% and -52·6% for secukinumab 300 mg and 150 mg, respectively. Skin clearance measured by ≥ 90% improvement in Psoriasis Area and Severity Index was significant (rates of 72·5%, 54·0% and 1·7% for secukinumab 300 mg and 150 mg and placebo at week 16, respectively, P < 0·001) and was sustained to week 32. The most common adverse events were nasopharyngitis, headache and upper respiratory tract infections. CONCLUSIONS: Secukinumab demonstrated significant and clinically meaningful efficacy and quality-of-life improvements for patients with nail psoriasis up to week 32. What's already known about this topic? Nail psoriasis is understudied and there is a lack of effective treatment options. Nail psoriasis is correlated with more severe psoriatic disease and the development of psoriatic arthritis. What does this study add? TRANSFIGURE is one of the few prospective placebo-controlled trials specifically in nail psoriasis and includes nail-specific quality-of-life measures such as Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA)-Quality of Life and NAPPA-Patient Benefit Index. In this trial, secukinumab demonstrates significant efficacy and quality-of-life improvements in this difficult-to-treat population.
引用
- Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019. PMID: 30367462. doi:10.1111/bjd.17351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。